+0.5%
AZN vs MRNA
+511.3%
-510.8%
-25.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.3% | -2.2% | +1.0% | -1.2% |
| 7D | 0.0% | +5.5% | -5.5% | -0.2% |
| 30D | +0.7% | +158.7% | -158.0% | -4.4% |
| 3M | -10.5% | +182.1% | -192.6% | -15.8% |
| 6M | -19.3% | +151.8% | -171.1% | -23.5% |
| YTD | -10.6% | +393.6% | -404.1% | -22.6% |
| 1Y | +0.5% | +499.5% | -499.0% | -19.4% |
| All | +0.5% | +511.3% | -510.8% | -19.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling